4.7 Review

Cell membrane-derived vesicles for delivery of therapeutic agents

Journal

ACTA PHARMACEUTICA SINICA B
Volume 11, Issue 8, Pages 2096-2113

Publisher

INST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCES
DOI: 10.1016/j.apsb.2021.01.020

Keywords

Cell membrane-derived vesicles; Membrane engineering; Drug-delivery systems; Blood cells; Immune cells; Stem cells; Cancer cells; Manufacturing

Funding

  1. Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Science and ICT (Republic of Korea) [NRF-2021R1A2B5B03002123, NRF-2018R1A5A2024425]
  2. Korea Medical Device Development Fund grant - Korea government (the Ministry of Science and ICT)
  3. Ministry of Trade, Industry and Energy
  4. Ministry of Health Welfare
  5. Ministry of Food and Drug Safety
  6. NTIS, Republic of Korea [9991007273]
  7. Korean Health Technology R&D Project (Republic of Korea) [HI18C2177, HI19C0664]

Ask authors/readers for more resources

Cell membrane-derived vesicles, with their unique multicomponent feature, have the potential to overcome various obstacles encountered in vivo and have created a new category of drug delivery systems. This technology has significant potential applications in the field of drug delivery.
Cell membranes have recently emerged as a new source of materials for molecular delivery systems. Cell membranes have been extruded or sonicated to make nanoscale vesicles. Unlike synthetic lipid or polymeric nanoparticles, cell membrane-derived vesicles have a unique multicomponent feature, comprising lipids, proteins, and carbohydrates. Because cell membrane-derived vesicles contain the intrinsic functionalities and signaling networks of their parent cells, they can overcome various obstacles encountered in vivo. Moreover, the different natural combinations of membranes from various cell sources expand the range of cell membrane-derived vesicles, creating an entirely new category of drug-delivery systems. Cell membrane-derived vesicles can carry therapeutic agents within their interior or can coat the surfaces of drug-loaded core nanoparticles. Cell membranes typically come from single cell sources, including red blood cells, platelets, immune cells, stem cells, and cancer cells. However, recent studies have reported hybrid sources from two different types of cells. This review will summarize approaches for manufacturing cell membrane-derived vesicles and treatment applications of various types of cell membrane-derived drug-delivery systems, and discuss challenges and future directions. (C) 2021 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available